Generalized Myasthenia Gravis
📧 Sign up to get email alerts when something new happens for Generalized Myasthenia Gravis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis [Phase 2, Phase 3]
A pediatric Phase 2/3 clinical trial is evaluating subcutaneous zilucoplan for generalized myasthenia gravis and is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis [Phase 2, Phase 3]
A pediatric Phase 2/3 trial of rozanolixizumab for generalized myasthenia gravis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis [Phase 3]
Open-label extension study evaluating zilucoplan for generalized myasthenia gravis is ongoing in Phase 3, with status active but not recruit…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis [Phase 3]
A Phase 3 clinical trial page outlining a study to compare remibrutinib with placebo in adults with generalized myasthenia gravis, currently…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis [Phase 3]
This clinical trial update reports enrollment for an open-label extension study of subcutaneous zilucoplan in pediatric participants with ge…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis [Phase 2, Phase 3]
Ongoing Phase 2/3 trial evaluating long-term safety of efgartigimod given IV and as a subcutaneous PH20 formulation in children with General…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod [Phase 2]
Phase 2 trial ADAPT Forward 1 evaluating Empasiprubart IV as add-on therapy to Efgartigimod IV in AChR-Ab seropositive generalized Myastheni…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) [Phase 3]
A Phase 3 clinical trial evaluating a new oral formulation of cladribine (MyClad) versus placebo in generalized myasthenia gravis, currently…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
The document provides an update on an AstraZeneca-sponsored clinical trial evaluating ravulizumab for generalized myasthenia gravis. Recruit…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
This clinical trial update indicates that a study evaluating the safety of Ravulizumab (Ultomiris) in pregnant and postpartum individuals is…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
AstraZeneca is sponsoring an epidemiological study in Russia on treatment approaches for AChR-antibody positive generalized myasthenia gravi…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab [Phase 4]
Phase 4 trial investigating tapering of oral corticosteroids in adults with generalized myasthenia gravis who are treated with ravulizumab; …
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) [Phase 2]
A Phase 2 study by Amgen is evaluating the pharmacokinetics, pharmacodynamics, safety, and tolerability of Inebilizumab in children with Gen…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis [Phase 2, Phase 3]
Kyverna Therapeutics' KYSA-6 anti-CD19 CAR-T therapy is being evaluated in Phase 2/3 trials for generalized myasthenia gravis, with recruitm…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis [Phase 3]
This is an update on a Phase 3 clinical trial evaluating the safety, PK/PD, and efficacy of Gefurulimab in pediatric patients with AChR-posi…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. [Phase 3]
A Phase III clinical trial evaluating iptacopan vs placebo for generalized myasthenia gravis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis [Phase 3]
Phase 3 study evaluating batoclimab for induction and maintenance therapy in adults with generalized myasthenia gravis. The trial is current…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) [Phase 3]
A Phase 3 clinical trial (UPSTREAM MG) is evaluating telitacicept for generalized myasthenia gravis and is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Zilucoplan for Severe gMG Exacerbations [Phase 3]
A Phase 3 clinical trial investigating Zilucoplan for severe exacerbations of Generalized Myasthenia Gravis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis [Phase 1, Phase 2]
This clinical trial update shows that Cabaletta Bio's experimental therapy CABA-201 is being evaluated in Phase 1/2 studies for generalized …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis [Phase 2, Phase 3]
A Phase 2/3 trial is evaluating intravenous efgartigimod in children with generalized myasthenia gravis. The study focuses on pharmacokineti…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
This clinical trial registry update describes a registry of participants with generalized myasthenia gravis treated with Alexion's C5 inhibi…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
This clinical trial update shows that ravulizumab is being studied as early treatment for anti-AChR antibody-positive generalized myasthenia…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Detecting Fatigue From Voice in Generalised Myasthenia Gravis
Thymia Limited is conducting a clinical trial to detect fatigue from voice in generalized myasthenia gravis; the study status is NOT_YET_REC…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis [Phase 2, Phase 3]
A pediatric Phase 2/3 study evaluating subcutaneous efgartigimod alfa-ph20 for generalized myasthenia gravis in children aged 2 to under 18 …